(Q41315122)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

review article

1 reference

title

Clinical development of topoisomerase-interactive drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

author name string

Burris HA

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

volume

29B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

page(s)

1-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996599%20AND%20SRC:MED&resulttype=core&format=json

Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor

22 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

DNA topoisomerase-trapping antitumour drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Characterization of camptothecin-resistant chinese hamster lung cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Antitumour Activity in a Series of bisDiketopiperazines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Prediction of complete remission in patients with refractory acute leukemia treated with AMSA

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

CI-921: an analog of amsacrine with experimental activity against solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Inhibition of topoisomerases by fredericamycin A

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

New anthracycline antitumor antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

A comparison of mitoxantrone and doxorubicin in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Paradoxical relationship between acetylator phenotype and amonafide toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

DNA topoisomerases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Protein-associated DNA breaks in cells treated with adriamycin or ellipticine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Qualitative and quantitative aspects of intercalator-induced DNA strand breaks

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

A phase II trial of CI-921 in advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

New natural products in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Phase II trial of ICRF-187 in children with solid tumors and acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961129-1

7 January 2021

10.1016/S1054-3589(08)61129-1

Identifiers

DOI

0 references

1 reference